Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abdullah Al-Asmi

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
Neurology and Therapy|May 17, 2025
Role of Immune Reconstitution Therapy with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in Older PatientsRaed Alroughani, Jihad Inshasi, Samar Farouk, et al.
Epilepsy & Behavior : E&B|September 10, 2013
Types and sociodemographic correlates of complementary and alternative medicine (CAM) use among people with epilepsy in OmanAbdullah Al Asmi, Abdullah Al Maniri, Yahya M Al-Farsi, et al.
Open Forum Infectious Diseases|March 4, 2015
Varicella zoster virus pneumonitis and brainstem encephalitis without skin rash in an immunocompetent adultRamachandiran Nandhagopal, Nelly Khmeleva, B Jayakrishnan, et al.
Epilepsy & Behavior : E&B|July 28, 2020
Epilepsy and school in the Middle East and North Africa (MENA) region: The current situation, challenges, and solutionsNajib Kissani, Khaoula Balili, Boulenouar Mesraoua, et al.
Cell Reports. Medicine|September 27, 2024
A candidate loss-of-function variant in SGIP1 causes synaptic dysfunction and recessive parkinsonismMarianna Decet, Patrick Scott, Sabine Kuenen, et al.
Scientific Reports|November 7, 2022
The diagnostic yield, candidate genes, and pitfalls for a genetic study of intellectual disability in 118 middle eastern familiesGhalia Al-Kasbi, Fathiya Al-Murshedi, Adila Al-Kindi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2024
Safety and effectiveness of disease-modifying therapies after switching from natalizumabMaya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 13, 2026
The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patientsGhida Ismail, Maya Zeineddine, Raed Al-Roughani, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched studyBassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Epilepsy & Behavior : E&B|June 15, 2023
A global survey on the attitudes of neurologists and psychiatrists about functional/psychogenic/dissociative/nonepileptic-seizures/attacks, in the search of its nameAli A Asadi-Pooya, Francesco Brigo, Eugen Trinka, et al.
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Neurology and Therapy|May 17, 2025
Role of Immune Reconstitution Therapy with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in Older PatientsRaed Alroughani, Jihad Inshasi, Samar Farouk, et al.
Epilepsy & Behavior : E&B|September 10, 2013
Types and sociodemographic correlates of complementary and alternative medicine (CAM) use among people with epilepsy in OmanAbdullah Al Asmi, Abdullah Al Maniri, Yahya M Al-Farsi, et al.
Open Forum Infectious Diseases|March 4, 2015
Varicella zoster virus pneumonitis and brainstem encephalitis without skin rash in an immunocompetent adultRamachandiran Nandhagopal, Nelly Khmeleva, B Jayakrishnan, et al.
Epilepsy & Behavior : E&B|July 28, 2020
Epilepsy and school in the Middle East and North Africa (MENA) region: The current situation, challenges, and solutionsNajib Kissani, Khaoula Balili, Boulenouar Mesraoua, et al.
Cell Reports. Medicine|September 27, 2024
A candidate loss-of-function variant in SGIP1 causes synaptic dysfunction and recessive parkinsonismMarianna Decet, Patrick Scott, Sabine Kuenen, et al.
Scientific Reports|November 7, 2022
The diagnostic yield, candidate genes, and pitfalls for a genetic study of intellectual disability in 118 middle eastern familiesGhalia Al-Kasbi, Fathiya Al-Murshedi, Adila Al-Kindi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2024
Safety and effectiveness of disease-modifying therapies after switching from natalizumabMaya Zeineddine, Raed Al-Roughani, Samar Farouk Ahmed, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 13, 2026
The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patientsGhida Ismail, Maya Zeineddine, Raed Al-Roughani, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched studyBassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Epilepsy & Behavior : E&B|June 15, 2023
A global survey on the attitudes of neurologists and psychiatrists about functional/psychogenic/dissociative/nonepileptic-seizures/attacks, in the search of its nameAli A Asadi-Pooya, Francesco Brigo, Eugen Trinka, et al.
Pageof 11